Partner Content Partner Content Poor Glycaemic Control and Tooth Loss Study Poor Glycaemic Control and Tooth Loss Study
Partner Content Partner Content First results of the DiabetRisk study First results of the DiabetRisk study
News Disappointment for BMS as Zeposia fails Crohn’s study Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.
Digital Sponsored Innovation as Strategy: Enabling life sciences of the future Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.